Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Articles   |    
Variation in Long-Term Antipsychotic Polypharmacy and High-Dose Prescribing Across Physicians and Hospitals
Eric A. Latimer, Ph.D.; Adonia Naidu, M.Sc., R.N.; Erica E. M. Moodie, Ph.D.; Robin E. Clark, Ph.D.; Ashok K. Malla, M.B.B.S., F.R.C.P.C.; Robyn Tamblyn, Ph.D.; Willy Wynant, M.S.
Psychiatric Services 2014; doi: 10.1176/appi.ps.201300217
View Author and Article Information

Dr. Latimer and Dr. Malla are with the Department of Psychiatry, McGill University, and the Douglas Mental Health University Institute, Montreal, Quebec, Canada (e-mail: eric.latimer@mcgill.ca). Ms. Naidu is with the Douglas Mental Health University Institute, Montreal. Dr. Moodie, Dr. Tamblyn, and Mr. Wynant are with the Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal. Dr. Clark is with the Center for Health Policy and Research, University of Massachusetts Medical School, Shrewsbury. Preliminary results from this study were presented at the Canadian Association for Health Services and Policy Research in Toronto, Ontario, May 11–14, 2010.

Copyright © 2014 by the American Psychiatric Association

text A A A
PDF of the full text article.

Objectives  This study had two aims: to measure the prevalence of long-term prescribing of high doses of antipsychotics and antipsychotic polypharmacy in a large Canadian province and to estimate the relative contributions of patient-, physician-, and hospital-level factors.

Methods  Government hospital discharge, physician, and pharmaceutical claims data were linked to identify individuals with schizophrenia who in 2004 had antipsychotics available to them for at least 11 months. Individuals on a high dose throughout that period, as well as individuals on multiple concurrent antipsychotics (polypharmacy), were identified. Logistic and generalized linear mixed models using patient-, physician-, and hospital-level predictors were estimated.

Results  Among the 12,150 individuals identified, 11.9% were on a high dose and 10.4% on antipsychotic polypharmacy continually, with 3.7% in both groups. After adjustment for potential confounders, analyses showed that systematic propensity for physicians to prescribe high doses accounted for 10.9% of the remaining unexplained variance, and physicians as a group who prescribed high doses across a hospital or psychiatry department accounted for 3.0%. For antipsychotic polypharmacy the corresponding percentages were 9.7% and 6.2%. Even after adjustment, the variation in high-dose prescribing and antipsychotic polypharmacy remained substantial.

Conclusions  Long-term high-dose and antipsychotic polypharmacy prescribing appeared partly driven by some physicians’ and some hospitals’ propensities to prescribe in this way independently of patient characteristics. Given the weight of the evidence against high-dose prescribing and antipsychotic polypharmacy, measures addressed to physicians and hospitals most likely to prescribe high doses, antipsychotic polypharmacy, or both should be considered.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 53.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 22.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 22.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles